These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 16793536)
21. A review of high throughput technology for the screening of natural products. Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498 [TBL] [Abstract][Full Text] [Related]
26. Target validation and drug discovery using genomic and protein-protein interaction technologies. Pillutla RC; Fisher PB; Blume AJ; Goldstein NI Expert Opin Ther Targets; 2002 Aug; 6(4):517-31. PubMed ID: 12223066 [TBL] [Abstract][Full Text] [Related]
27. Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats. Seneci P; Miertus S Mol Divers; 2000; 5(2):75-89. PubMed ID: 11865648 [TBL] [Abstract][Full Text] [Related]
28. Small-molecule screening: advances in microarraying and cell-imaging technologies. Nicholson RL; Welch M; Ladlow M; Spring DR ACS Chem Biol; 2007 Jan; 2(1):24-30. PubMed ID: 17243780 [TBL] [Abstract][Full Text] [Related]
29. The Development of Protein Chips for High Throughput Screening (HTS) of Chemically Labeling Small Molecular Drugs. Feng Y; Wang B; Chu X; Wang Y; Zhu L Mini Rev Med Chem; 2016; 16(10):846-50. PubMed ID: 25963567 [TBL] [Abstract][Full Text] [Related]
31. Forecasting roles of combinatorial chemistry in the age of genomically derived drug discovery targets. Thorpe DS Comb Chem High Throughput Screen; 2000 Oct; 3(5):421-36. PubMed ID: 11032958 [TBL] [Abstract][Full Text] [Related]
33. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'. Campbell JB IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146 [TBL] [Abstract][Full Text] [Related]
34. Applications of random sampling to virtual screening of combinatorial libraries. Beroza P; Bradley EK; Eksterowicz JE; Feinstein R; Greene J; Grootenhuis PD; Henne RM; Mount J; Shirley WA; Smellie A; Stanton RV; Spellmeyer DC J Mol Graph Model; 2000; 18(4-5):335-42. PubMed ID: 11143553 [TBL] [Abstract][Full Text] [Related]
35. Selection criteria for drug-like compounds. Muegge I Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312 [TBL] [Abstract][Full Text] [Related]
36. Exploring the chemogenomic knowledge space with annotated chemical libraries. Savchuk NP; Balakin KV; Tkachenko SE Curr Opin Chem Biol; 2004 Aug; 8(4):412-7. PubMed ID: 15288252 [TBL] [Abstract][Full Text] [Related]
37. Functional protein micropatterning for drug design and discovery. You C; Piehler J Expert Opin Drug Discov; 2016; 11(1):105-19. PubMed ID: 26624534 [TBL] [Abstract][Full Text] [Related]
38. Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets. Vogt A; Lazo JS Pharmacol Ther; 2005 Aug; 107(2):212-21. PubMed ID: 15925410 [TBL] [Abstract][Full Text] [Related]
39. Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631 [TBL] [Abstract][Full Text] [Related]
40. Functional cell-based uHTS in chemical genomic drug discovery. Croston GE Trends Biotechnol; 2002 Mar; 20(3):110-5. PubMed ID: 11841862 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]